Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specified Drug Use resulTs survEy of IpragLifLozin treAtment in ELDERly type2 Diabetes Patients (STELLA-ELDER)

NCT02297620 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02297620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02297620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specified Drug Use resulTs survEy of IpragLifLozin treAtment in ELDERly type2 Diabetes Patients (STELLA-ELDER)
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
April 30, 2014
Completion date
July 31, 2015
Enrollment
8,687 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes